BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 38474373)

  • 21. Growing knowledge of the mTOR signaling network.
    Huang K; Fingar DC
    Semin Cell Dev Biol; 2014 Dec; 36():79-90. PubMed ID: 25242279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevention of Akt phosphorylation is a key to targeting cancer stem-like cells by mTOR inhibition.
    Matsubara S; Tsukasa K; Kuwahata T; Takao S
    Hum Cell; 2020 Oct; 33(4):1197-1203. PubMed ID: 32851605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapamycin attenuates BAFF-extended proliferation and survival via disruption of mTORC1/2 signaling in normal and neoplastic B-lymphoid cells.
    Zeng Q; Qin S; Zhang H; Liu B; Qin J; Wang X; Zhang R; Liu C; Dong X; Zhang S; Huang S; Chen L
    J Cell Physiol; 2018 Jan; 233(1):516-529. PubMed ID: 28300280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling.
    Wang B; Jie Z; Joo D; Ordureau A; Liu P; Gan W; Guo J; Zhang J; North BJ; Dai X; Cheng X; Bian X; Zhang L; Harper JW; Sun SC; Wei W
    Nature; 2017 May; 545(7654):365-369. PubMed ID: 28489822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Small molecule H89 renders the phosphorylation of S6K1 and AKT resistant to mTOR inhibitors.
    Melick CH; Jewell JL
    Biochem J; 2020 May; 477(10):1847-1863. PubMed ID: 32347294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Protein kinase N controls a lysosomal lipid switch to facilitate nutrient signalling via mTORC1.
    Wallroth A; Koch PA; Marat AL; Krause E; Haucke V
    Nat Cell Biol; 2019 Sep; 21(9):1093-1101. PubMed ID: 31451768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rapamycin prevents cadmium-induced neuronal cell death via targeting both mTORC1 and mTORC2 pathways.
    Xu C; Liu C; Liu L; Zhang R; Zhang H; Chen S; Luo Y; Chen L; Huang S
    Neuropharmacology; 2015 Oct; 97():35-45. PubMed ID: 26002629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of PI3K-Akt-mTOR signaling in glioblastoma by mTORC1/2 inhibitors.
    Fan QW; Weiss WA
    Methods Mol Biol; 2012; 821():349-59. PubMed ID: 22125077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epstein-Barr Virus LMP1-Activated mTORC1 and mTORC2 Coordinately Promote Nasopharyngeal Cancer Stem Cell Properties.
    Zhu N; Wang Q; Wu Z; Wang Y; Zeng MS; Yuan Y
    J Virol; 2022 Mar; 96(5):e0194121. PubMed ID: 35019715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual PI3K/mTOR Inhibitors Induce Rapid Overactivation of the MEK/ERK Pathway in Human Pancreatic Cancer Cells through Suppression of mTORC2.
    Soares HP; Ming M; Mellon M; Young SH; Han L; Sinnet-Smith J; Rozengurt E
    Mol Cancer Ther; 2015 Apr; 14(4):1014-23. PubMed ID: 25673820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.
    Heinzen D; Divé I; Lorenz NI; Luger AL; Steinbach JP; Ronellenfitsch MW
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. mTOR Ser-2481 autophosphorylation monitors mTORC-specific catalytic activity and clarifies rapamycin mechanism of action.
    Soliman GA; Acosta-Jaquez HA; Dunlop EA; Ekim B; Maj NE; Tee AR; Fingar DC
    J Biol Chem; 2010 Mar; 285(11):7866-79. PubMed ID: 20022946
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regulation of mTOR Signaling: Emerging Role of Cyclic Nucleotide-Dependent Protein Kinases and Implications for Cardiometabolic Disease.
    Shi F; Collins S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511253
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic modeling of signal transduction by mTOR complexes in cancer.
    Dorvash M; Farahmandnia M; Mosaddeghi P; Farahmandnejad M; Saber H; Khorraminejad-Shirazi M; Azadi A; Tavassoly I
    J Theor Biol; 2019 Dec; 483():109992. PubMed ID: 31493485
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting cancer stem cells in glioblastoma multiforme using mTOR inhibitors and the differentiating agent all-trans retinoic acid.
    Friedman MD; Jeevan DS; Tobias M; Murali R; Jhanwar-Uniyal M
    Oncol Rep; 2013 Oct; 30(4):1645-50. PubMed ID: 23877261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic Target of Rapamycin Signaling Activation Antagonizes Autophagy To Facilitate Zika Virus Replication.
    Sahoo BR; Pattnaik A; Annamalai AS; Franco R; Pattnaik AK
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32878890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
    Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
    Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective interference of mTORC1/RAPTOR protects against human disc cellular apoptosis, senescence, and extracellular matrix catabolism with Akt and autophagy induction.
    Ito M; Yurube T; Kakutani K; Maeno K; Takada T; Terashima Y; Kakiuchi Y; Takeoka Y; Miyazaki S; Kuroda R; Nishida K
    Osteoarthritis Cartilage; 2017 Dec; 25(12):2134-2146. PubMed ID: 28888905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
    Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
    Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.